Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

 Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China

Shots:

  • Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory
  • 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions
  • Both the companies will share IND development costs. YBL-013 is a T cell bi-specific engager based on ALiCE platform technology and targets CD3 on T cell and PD-L1 on cancer cell

Click here ­to­ read full press release/ article | Ref: PRNasia | Image: Y-Biologics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post